

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT-2777A US - CIP (1)

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, et al.

FILING DATE 05 DEC 2003



U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
VB	AA	11/247,697 [10243-NP]	11 OCT 2005	Chaturvedula, <u>et al.</u>			
VB	AB	11/291,670 [10466-NP]	01 DEC 2005	Chaturvedula, <u>et al.</u>			
	AC						
	AD						

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
VB	AE	2001/0036946 A1	01 NOV 2001	Rudolf, <u>et al.</u>			
VB	AF	2003/0191068 A1 [English equivalent of WO 03/070753]	09 OCT 2003	Trunk and Weiler			
VB	AG	2004/0214819 A1	28 OCT 2004	Rudolf, <u>et al.</u>			
VB	AH	2004/0229861 A1	18 NOV 2004	Burgey, <u>et al.</u>			
VB	AI	2004/0248816A1	09 DEC 2004	Doods, <u>et al.</u>			
VB	AJ	2005/0032783 A1	10 FEB 2005	Doods, <u>et al.</u>			
VB	AK	2005/0065094 A1	24 MAR 2005	Davidai			
VB	AL	2005/0215546 A1	29 SEP 2005	Hurnaus, <u>et al.</u>			
VB	AM	2005/0215576 A1 [10260-NP]	29 SEP 2005	Degnan, <u>et al.</u>			
VB	AN	2005/0227968 A1 [English equivalent of WO2005/084672]	05 OCT 2005	Lustenberger, <u>et al.</u>			
VB	AO	2005/0233980 A1 [English equivalent of WO2005/102322]	20 OCT 2005	Doods and Rudolf			
VB	AP	2005/0234054 A1	20 OCT 2005	Mueller, <u>et al.</u>			
VB	AQ	2005/0234067 [English equivalent of WO2005/092880]	20 OCT 2005	Mueller, <u>et al.</u>			
VB	AR	2005/0250763 A1	10 NOV 2005	Mueller, <u>et al.</u>			
VB	AS	2005/0256098	17 NOV 2005	Burgey, <u>et al.</u>			

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT-2777A US - CIP (1)

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, et al.

FILING DATE 05 DEC 2003

U.S. PATENT APPLICATION PUBLICATIONS, *continued*

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<i>M</i>	AT	US2005/0256099 [English equivalent of WO2005/103037]	17 NOV 2005	Mueller, <u>et al.</u>			
<i>M</i>	AU	2005/0272955 A1 [English equivalent of WO2005/121078]	08 DEC 2005	Zimmer, <u>et al.</u>			
	AW						
	AX						
	AY						
	AZ						

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	APPLICANT	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
<i>M</i>	BE	WO 03/070753] [see English equivalent US 2003/191068]	28 AUG 2003	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>M</i>	BF	WO 2004/087649 A2	14 OCT 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
<i>M</i>	BG	WO 2004/092168A1	28 OCT 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
<i>M</i>	BH	WO 2004/092166A2	28 OCT 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT-2777A US - CIP (1)

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, *et al.*

FILING DATE 05 DEC 2003

FOREIGN PATENT DOCUMENTS, continued

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	APPLICANT	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
WY	BI	WO 2005/000807	06 JAN 2005	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
WY	BJ	WO 2005/009962	03 FEB 2005	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
WY	BK	WO 2005/013894	17 FEB 2005	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
WY	BL	WO2005/065779 [10135 PCT]	21 JUL 2005	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
WY	BM	WO 2005/072308	11 AUG 2005	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
WY	BN	WO 2005/095383 [10260-PCT]	13 OCT 2005	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
WY	BO	WO 2005/102322 (see English equivalent US 2005/0233980]	03 NOV 2005	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
WY	BP	WO 2005/092880 [see English equivalent 2005/0234067]	06 OCT 2005	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
WY	BQ	WO 2005/100343 [English Abstract]	27 OCT 2005	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input checked="" type="checkbox"/>
WY	BR	WO 2005/100352 [English Abstract]	27 OCT 2005	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input checked="" type="checkbox"/>
WY	BS	WO/2005/100360 [English Abstract]	27 OCT 2005	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input checked="" type="checkbox"/>
WY	BT	WO 2005/103037 [see English equivalent US2005/0256099]	03 NOV 2005	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
WY	BU	WO 2005/121078 [see English equivalent 2005/0272955]	22 DEC 2005	Grünenthal GMBH			<input checked="" type="checkbox"/>	<input type="checkbox"/>
WY	BV	WO2005/084672 [see English equivalent 2005/0227968]	15 SEP 2005	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/>	<input type="checkbox"/>
WY	BW							

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CT-2777A US - CIP (1)

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, *et al.*

FILING DATE 05 DEC 2003

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

<i>cy</i>	BX	CARLSTRÖM, A.-S. and FREJD, T., "Palladium-Catalyzed Synthesis of Didehydroamino Acid Derivatives, <i>Synthesis</i> , 1989, 6, 414-418
<i>ly</i>	BY	CARLSTRÖM, A.-S. and FREJD, T., "Palladium-Catalyzed Bis-coupling of Dihaloaromatics with 2-Amidoacrylates", <i>J. Org. Chem.</i> , 1991, 56, 1289-1293
<i>ly</i>	BZ	DYGOS, J.H., <i>et al.</i> , "A Convenient Asymmetric Synthesis of the Unnatural Amino Acid 2,6-Dimethyl-L-tyrosine", <i>Synthesis</i> , 1992, 741-743
<i>ly</i>	CA	RUDOLF, K., <i>et al.</i> , "Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. 1. Potent and Selective Small Molecule CGRP Antagonists. 1-[N ² -[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl] L-lysyl]-4-(4-pyridinyl)piperazine: The First CGRP Antagonist for Clinical Trials in Acute Migraine", <i>J. Med. Chem.</i> 2005, 48, 5921-5931
<i>ly</i>	CB	XIN, Z., <i>et al.</i> , "Potent, Selective Inhibitors of Protein Tyrosine Phosphatase 1B", <i>Bioorg. & Med. Chem. Lett.</i> , 2003, 13, 1887-1890
	CC	
	CD	
	CE	
	CF	

EXAMINER

V. Balasubramanian


DATE CONSIDERED

3/12/06

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT2777A
APPLICATION NO.
10/729,155
APPLICANT
CHATURVEDULA ET AL.
FILING DATE
DECEMBER 5, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
VB	AA	US 6,344,449 B1	2/5/02	Rudolf et al.			
VB	AB	US 6,552,043 B1	4/22/03	Patchett et al.			
VB	AC	US 6,521,609 B1	2/18/03	Doods et al.			
VB	AD	US 6,313,097 B1	11/6/01	Eberlein, et al.			
VB	AE	US 2003/0181462	9/25/03	Doods, et al.			
VB	AF	US 2003/0191068	10/9/03	Trunk, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
VB	AG	WO 01/25228 A1	4/12/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
VB	AH	WO 99/52875	10/21/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
VB	AI	WO 01/32649A1	5/10/01	PCT [CA 2387613 English equiv]			<input type="checkbox"/>	<input type="checkbox"/>
VB	AJ	WO 00/55154	9/21/00	PCT [US 6,313,097 English equiv]			<input type="checkbox"/>	<input type="checkbox"/>
VB	AK	WO 98/11128	3/19/98	PCT [U.S. 6,344,449 English equiv]				
VB	AL	WO 00/18764	4/6/00	PCT				
VB	AM	WO 01/32648 A1	5/10/01	PCT				
VB	AN	WO 98/56779	12/17/98	PCT				
VB	AO	WO 98/09630	3/12/98	PCT				
VB	AP	WO 97/09046	3/13/97	PCT				
VB	AQ	WO 03/027252 A2	4/3/03	PCT				
VB	AR	WO 01/49676 A1	7/12/01	PCT [CA 2395541 English equivalent]				
VB	AS	WO 03/076432	9/18/03	PCT [no English equivalent]				

EXAMINER

V. Balasubramanian


DATE CONSIDERED

3/12/06

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT2777A
APPLICATION NO.
10/729,155
APPLICANT
CHATURVEDULA ET AL.
FILING DATE
DECEMBER 5, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

VB	2AA	HALL, et al., "Interaction of human adrenomedullin 13-52 with calcitonin gene-related peptide receptors in the microvasculature of the rat and hamster," <u>British Journal of Pharmacology</u> , 1995, 114, 592-597
VB	2AB	HALL, et al., "Interaction of amylin with calcitonin gene-related peptide receptors in the microvasculature of the hamster cheek pouch <i>in vivo</i> ," <u>British Journal of Pharmacology</u> , 1999, 126, 280-284
VB	2AC	DOODS, et al., "Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist," <u>British Journal of Pharmacology</u> , 2000, 129, 420-423
VB	2AD	CHU, et al., "The calcitonin gene-related peptide (CGRP) antagonist CGRP8-37 blocks vasodilatation in inflamed rat skin: involvement of adrenomedullin in addition to CGRP," <u>Neuroscience Letters</u> , 310, 2001, 169-172
VB	2AE	WILLIAMSON, et al., "Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies," <u>Cephalalgia</u> , 1997, 17, 525-531
VB	2AF	ESCOTT, et al., "Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve," <u>British Journal of Pharmacology</u> , 1993, 110, 772-776
VB	2AG	ESCOTT, et al., "Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide," <u>Brain Research</u> , 669, 1995, 93-99
VB	2AH	WILLIAMSON, et al., "Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat," <u>Cephalalgia</u> , 1997, 17, 518-524
VB	2AI	DE VRIES, et al., "Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy," <u>European Journal of Pharmacology</u> , 375, 1999, 61-74
VB	2AJ	SHEN, et al., "Functional role of α -calcitonin gene-related peptide in the regulation of the cardiovascular system," <u>Journal of Pharmacology and Experimental Therapeutics</u> , 2001, 298, 2, 551-558
VB	2AK	LASSEN, et al., "CGRP may play a causative role in migraine," <u>Cephalalgia</u> , 2002, 22, 54-61
VB	2AL	ASHINA, et al., "Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks," <u>Pain</u> , 86, 2000, 133-138
VB	2AM	GALLAI, et al., "Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally," <u>Cephalalgia</u> , 1995, 15, 384-390
VB	2AN	GOADSBY, et al., "Vasoactive peptide release in the extracerebral circulation of humans during migraine headache," <u>Annals of Neurology</u> , 1990, 28, 2, 183-187

EXAMINER

V. Balasubramanian

DATE CONSIDERED

3/12/06


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT2777A
APPLICATION NO.
10/729,155
APPLICANT
CHATURVEDULA ET AL.
FILING DATE
DECEMBER 5, 2003

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

W	3AA	GRANT, et al., "Evidence of a role for NK1 and CGRP receptors in mediating neurogenic vasodilatation in the mouse ear," <u>British Journal of Pharmacology</u> , 2002, 135, 356-362
W	3AB	WILLIAMSON, et al., "Neurogenic inflammation in the context of migraine," <u>Microscopy Research and Technique</u> , 2001, 53, 167-178
W	3AC	EDVINSSON, "Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache," <u>CNS Drugs</u> , 2001, 15, 10, 745-753
W	3AD	BRAIN, et al., "CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine?," <u>Trends in Pharmacological Sciences</u> , 2/2002, 23, 51-53
W	3AE	JUANEDA, et al., "The molecular pharmacology of CGRP and related peptide receptor subtypes," <u>Trends in Pharmacological Sciences</u> , 11/2000, 21, 432-438
W	3AF	POYNER, et al., "Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes," <u>Br. J. Pharmacol</u> , 1992, 105, 441-447
W	3AG	VAN VALEN, et al., "Calcitonin gene-related peptide (CGRP) receptors are linked to cyclic adenosine monophosphate production in SK-N-MC human neuroblastoma cells," <u>Neuroscience Letters</u> , 1990, 119, 195-198
W	3AH	EVANS, et al., "CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors," <u>Journal of Biological Chemistry</u> , 2000, 275, 409, 31438-31443
W	3AI	MCLATCHIE, et al., "RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor," <u>Nature</u> , 1998, 393, 333-339
W	3AJ	MALLEE, et al., "Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists," <u>Journal of Biological Chemistry</u> , 2002, 277, 16, 14294-14298
W	3AK	AMARA, et al., "Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products," <u>Nature</u> , 1982, 298, 240-244
	3AL	
	3AM	
	3AN	

EXAMINER

V. Balasubramanian

DATE CONSIDERED


3/12/06

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO. CT2777A-CIP

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, et al.

FILING DATE December 5, 2003 GROUP

U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
VB	AA	60/624,655 [10243PSP]	03 Nov 2004	Chaturvedula, <u>et al.</u>			
VB	AB	60/678,099 [10243PSP2]	05 May 2005	Chaturvedula, <u>et al.</u>			
VB	AC	60/633,159 [10466PSP]	03 Dec 2004	Chaturvedula, <u>et al.</u>			
VB	AD	11/091,429 [10260NP]	28 Mar 2005	Degnan, <u>et al.</u>			
	AE						

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
VB	AF	US 2003/0139417 A1	24 Jul 2003	Eberlein, <u>et al.</u>			
VB	AG	US 2003/0212057 A1	13 Nov 2003	Rudolf, <u>et al.</u>			
M	AH	US 2003/0236282 A1	12 Dec 2003	Humaus, <u>et al.</u>			
M	AI	US 2004/0014679 A1	22 Jan 2004	Trunk and Weiler			
M	AJ	US 2004/0076587 A1	22 Apr 2004	Kruss, <u>et al.</u>			
M	AK	US 2004/0132716 A1	08 Jul 2004	Rudolf, <u>et al.</u>			
M	AL	US 2004/0192729 A1	30 Sep 2004	Rudolf, <u>et al.</u>			
VB	AM	US2004/0204397 A1 [CT2777A-CIP]	14 Oct 2004	Chaturvedula, <u>et al.</u>			
VB	AN	US2004/0063735 A1 [CT2777NP]	01 Apr 2004	Chaturvedula, <u>et al.</u>			
VB	AO	US 2005/0153959-A1 [10114-NP]	14 Jul 2005	Luo, <u>et al.</u>			
	AP						

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AQ						
	AR						

FORM PTO-1449
(REV. 7-85)

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

INFORMATION DISCLOSURE CITATION


(Use several sheets if necessary)

ATTY. DOCKET NO. CT2777A-CIP

APPLICATION NO. 10/729,155

APPLICANT **Chaturvedula, et al.**

FILING DATE December 5, 2003 GROUP



FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	APPLICANT	CLASS	SUB-CLASS	TRANSLATION YES NO	
VB	AS	CA 2 387 613	10 May 2001	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input type="checkbox"/>
W	AT	CA 2 503 455 (English translation of WO2004/037810, see "AX")	22 Apr 2005	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input type="checkbox"/>
W	AU	EP 1 227 090 A1	31 Jul 2002	Tadeca Chemical Industries,			<input type="checkbox"/>	<input type="checkbox"/>
W	AV	WO 02/10140	7 Feb 2002	Societe De Conseils De Recherches Et D'Applications Scientifiques (S.C.R.A)			<input type="checkbox"/>	<input type="checkbox"/>
W	AW	WO 03/104236 [CT2777-PCT]	18 Dec 2003	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
W	AX	WO 2004/037810	6 May 2004	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/> [see "AT"]	<input type="checkbox"/>
W	AY	WO 2004/082602 A2	30 Sep 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
W	AZ	WO 2004/082605 A2	30 Sep 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
W	BA	WO 2004/082678 A1	30 Sep 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
W	BB	WO 2004/083187 A1	30 Sep 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
W	BC	WO 2004/091514 A2	28 Oct 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
W	BD	WO 2004/092166 A2	28 Oct 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
W	BE	WO 2004/092168 A1	28 Oct 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
W	BF	WO 2005/056550 [10114-PCT]	23 Jun 2005	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
	BG							
	BH							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

VB	BI	OLESEN, J. <u>et al.</u> , "Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine", <u>New England J. of Medicine</u> , 2004, 350 (11): 1104-1110
VB	BJ	PASTERNAK, et al., "Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization", <u>Bioorganic & Medicinal Chemistry</u> Letters, Oxford GB, Vol. 9, No. 3, 8 Feb 1999, 491-496

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION


(Use several sheets if necessary)

ATTY. DOCKET NO. CT2777A-CIP

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, et al.

FILING DATE December 5, 2003 GROUP



BK	ROSENFELD, <i>et al.</i> , "Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing", <i>Nature</i> , 1983, 304:129-135
BL	
BM	
BN	
BO	

EXAMINER

V. Balasubramanian

DATE CONSIDERED

3/12/06

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.